SELEGILINE AS A TREATMENT FOR POST-TRAUMATIC COGNITIVE DYSFUNCTION

司来吉兰治疗创伤后认知功能障碍

• 批准号: 7605006
• 负责人: JEFFERY J ERICKSEN
• 金额: $ 0.07万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-20 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605006
• 关键词: Address; Area; Computer Retrieval of Information on Scientific Projects Database; Disease; Effectiveness; Funding; Grant; Headache; Impaired cognition; Individual; Inpatients; Institution; Intervention; Intervention Trial; Medical center; Morbidity - disease rate; Neuropsychological Tests; Outcome Measure; Public Health; Randomized; Recovery; Research; Research Personnel; Resources; Score; Selegiline; Source; Traumatic Brain Injury; United States National Institutes of Health; cognitive function; double-blind placebo controlled trial; mortality; nervous system disorder; programs; ward

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Traumatic brain injury (TBI) is an increasing area of public health concern. More than 2 million individuals sustain TBI each year. Disorders arising from TBI are more common than any other neurological disease except headache. Interventions to reduce the morbidity and mortality associated with TBI are urgently needed. This study will attempt to address these issues by exploring the following hypothesis: Can selegiline enhance recovery of cognitive functioning in individuals who recently sustained mild TBI? Subjects will include individuals with mild TBI admitted and discharged from the inpatient wards of the VCU Medical Center. This program of research will examine the effectiveness of selegiline in a limited randomized, double-blind, placebo-controlled trial. Results from this study will be used to determine if larger trials of this intervention are warranted. The primary outcome measures for documenting recovery will be improvement in neuropsychological test scores.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 创伤性脑损伤（TBI）是公共卫生关注的越来越多的领域。 每年有超过200万人维持TBI。 由TBI引起的疾病比头痛以外的任何其他神经系统疾病更常见。 迫切需要采取干预措施以降低与TBI相关的发病率和死亡率。这项研究将尝试通过探索以下假设来解决这些问题：Selegiline可以增强最近持续轻度TBI的个体认知功能的恢复吗？ 受试者将包括接纳和从VCU医疗中心住院病房出院的轻度TBI的人。 该研究计划将检查塞勒吉林在有限的随机，双盲，安慰剂对照试验中的有效性。 这项研究的结果将用于确定是否有必要进行此干预措施的较大试验。 记录恢复的主要结果指标将是神经心理测试评分的改善。